A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.

Jemal HusseinMartha ZewdieLawrence YamuahAhmed BedruMarkos AbebeAlemnew F DagnewMenberework ChanyalewAsfawesen G YohannesJemal AhmedHoward EngersT Mark DohertyPeter BangIngrid KromannSøren T HoffAbraham Aseffa

Published in: Trials (2018)

ClinicalTrials.gov, ID: NCT01049282. Retrospectively registered on 14 January 2010.

Keyphrases

open label
phase iii
phase ii
mycobacterium tuberculosis
study protocol
clinical trial
phase ii study
pulmonary tuberculosis
randomized controlled trial
hiv aids
protein kinase
placebo controlled
double blind
emergency department
squamous cell carcinoma
adverse drug